SlideShare a Scribd company logo
1 of 32
Download to read offline
Transforming Clinical Development
through Digital Biomarkers (dBMs)
Emily (Kunka) Lewis, MS, CCRP
Digital Business Transformation, Neurology
UCB Biopharma
2
Proprietary
and
Confidential
Property
of
UCB
2
Proprietary
and
Confidential
Property
of
UCB
UCB is a global
biopharmaceutical
company focused on
solutions for people
living with severe
diseases.
By putting people at the
heart of everything we do,
we enable people to live
their best lives, as free
as possible from the
challenges of disease.
From Solution
to Patient
We strive for a unique
patient experience,
providing solutions
with the highest
possible impact.
From Patient
to Science
We pursue a deep
understanding of patient
sub-populations to
develop an original
scientific hypothesis.
From Science to Solution
We aim to translate scientific hypotheses into
innovative solutions and engage patients in the journey.
3
Proprietary
and
Confidential
Property
of
UCB
3
Proprietary
and
Confidential
Property
of
UCB
UCB’s patient value ambition
UCB Team Name [XXXXXXX] - UCB - Approval [XX-XX-XXX] - Approval date [XX Month XXXX] ! GO TO INSERT>HEADER FOOTER to change.
Creating value for patients now and into the future
Unique outcomes that
help specific patients
achieve their goals
Best individual
experience
Ensuring access to all
those who need these
solutions in a way which
is viable for patients,
society, and UCB
4
Proprietary
and
Confidential
Property
of
UCB
4
Proprietary
and
Confidential
Property
of
UCB
Becoming more customer and
data-centric in our approach Developing digital platforms for
personalized patient care and
disease identification
Digital mindset Using data and technology
with purpose
Partnering externally for
greater impact
Our digital business transformation journey:
a strategic priority
5
Proprietary
and
Confidential
Property
of
UCB
5
Proprietary
and
Confidential
Property
of
UCB
Digital
Transformation
Data and Real
World Evidence
Open
Innovation
We continuously innovate
References: 1. UCB 2021 Annual Report.
R&D
28%1
UCB invests about a
quarter of its revenue
in R&D annually
Continual Investment in
Research & Development
6
Proprietary
and
Confidential
Property
of
UCB
6
Proprietary
and
Confidential
Property
of
UCB
The Evolution of Digital Health in Life Sciences
Testing Contemplation Innovation Realization
2010 2015 2020 2023
● Testing and
piloting of
isolated point
solution →
“pilotitis”
● Application of
“blue sky”
thinking
● Opportunistic
lens
● Advanced
experimentation
with increased
risk
● Struggle to
show ROI as
outcomes have
not met lofty
expectations
● Shift to strategic
lens
● Investment hike
● Iterative and
agile
experimentation
● Digital
ecosystem
development
● Increased
adoption due to
regulatory
advancements
and roll backs
● Seen as an
enabler for
achieving
strategic
objectives and
incremental
value creation
● Enterprise level
adoption and
scale with
revenue
streams
7
Proprietary
and
Confidential
Property
of
UCB
7
Proprietary
and
Confidential
Property
of
UCB
Life Science companies must be guided by
enterprise strategies that prioritize the
delivery of purposeful, multi-pronged, yet
integrated treatment experiences
So, What Have We Learned?
8
Proprietary
and
Confidential
Property
of
UCB
8
Proprietary
and
Confidential
Property
of
UCB
What are Digital Biomarkers?
Sensors in
Connected
Devices
Computational
Methods
Digital
Biomarkers
Health indicators that are collected through digital devices which
can provide objective, real-time, continuous,
high-resolution data about a person’s physiological and
behavioral status.
9
Proprietary
and
Confidential
Property
of
UCB
9
Proprietary
and
Confidential
Property
of
UCB
Types of dBMs
Predictive
03
Biomarker used to identify individuals who are more
likely than similar individuals without the biomarker to
experience a favorable or unfavorable effect from
exposure to a medical productor environmental agent
Monitoring
02
Biomarker measured repeatedly for assessing
status of a disease or medical condition or for
evidence of exposure to (or effect of) a medical
product or an environmental agent
Diagnostic
01
Biomarker used to detect or confirm the presence
of a disease or condition of interest or identify
individuals with a subtype of the disease
PD/Response
06
Biomarker used to show that a biological
response, potentially beneficial or harmful, has
occurred in an individual who has been exposed
to a medical product or an environmental agent
Safety
05
Biomarker measured before or after an exposure
to a medical product or an environmental agent to
indicate the likelihood. presence, or extent of
toxicity as an adverse event
Prognostic
04
Biomarker used to identify likelihood of a clinical
event, disease recurrence or progression in
patients who have the disease or medical
condition of interest
Susceptibility/Risk
07
Biomarker that indicates the potential for
developing a disease or medical condition in an
individual who does not currently have clinically
apparent disease or the medical condition
Biomarkers,
EndpointS
and other
Tools
(BEST)
Framework
10
Proprietary
and
Confidential
Property
of
UCB
10
Proprietary
and
Confidential
Property
of
UCB
Current Applications
Sleep
Speech
Behavioral
Habits
Activity
step count
heart rate
Cognitive
Assessments
Gait
stride velocity
bradykinesia
11
Proprietary
and
Confidential
Property
of
UCB
11
Proprietary
and
Confidential
Property
of
UCB
Key Questions to Navigate
● What to measure?
● How do we measure it? What
is the right tool?
○ What is needed to deploy
remotely at scale?
○ How do we validate it?
○ How do we analyze it?
● Why is it important?
● What do we want to achieve?
● What is the right regulatory
pathway?
● How will we integrate it into
clinical practice?
12
Proprietary
and
Confidential
Property
of
UCB
12
Proprietary
and
Confidential
Property
of
UCB
Identifying What to Measure
Determine the MAH
● Determine the
meaningful aspect of
health (MAH)
● Identify the concept
of interest (COI)
● Define the digital
measure (e.g.
outcome/endpoint)
Understand Patient Journey
● A disease is more than
just a collection of
symptoms and issues.
● Understand the
nuances of the
condition that drive
patient decisions and
behaviors.
ID Specific Pain Points
● Identify the wider context
of the patient experience
● In what capacity would
digital measurement fit
into the patient journey?
13
Proprietary
and
Confidential
Property
of
UCB
13
Proprietary
and
Confidential
Property
of
UCB
What is the Right Tool? How Do we Measure It?
1
C
o
m
p
l
e
t
e
t
h
e
V
3
F
r
a
m
e
w
o
r
k
V
e
r
i
f
i
c
a
t
i
o
n
,
A
n
a
l
y
t
i
c
a
l
V
a
l
i
d
a
t
i
o
n
,
C
l
i
n
i
c
a
l
V
a
l
i
d
a
t
i
o
n
2
A
s
s
e
s
s
U
t
i
l
i
t
y
a
n
d
U
s
a
b
i
l
i
t
y
C
o
n
d
u
c
t
h
u
m
a
n
f
a
c
t
o
r
s
r
e
s
e
a
r
c
h
t
o
a
s
s
e
s
s
u
s
e
r
e
x
p
e
r
i
e
n
c
e
,
b
a
t
t
e
r
y
l
i
f
e
,
c
l
i
n
i
c
a
l
r
e
l
e
v
a
n
c
e
,
a
d
h
e
r
e
n
c
e
3
A
s
s
e
s
s
D
a
t
a
S
e
c
u
r
i
t
y
a
n
d
P
r
i
v
a
c
y
E
n
s
u
r
e
a
d
e
q
u
a
t
e
d
a
t
a
s
t
o
r
a
g
e
p
r
o
c
e
s
s
i
n
g
,
a
n
d
a
c
c
e
s
s
14
Proprietary
and
Confidential
Property
of
UCB
14
Proprietary
and
Confidential
Property
of
UCB
Why Are dBMs Important in R&D?
Disease
Heterogeneity
Difficult-to-Measure
Disease States
Treatment
Effect
15
Proprietary
and
Confidential
Property
of
UCB
15
Proprietary
and
Confidential
Property
of
UCB
Why Are dBMs Important in R&D?
● Capture health status in
the real world, passively,
continuously over 365 days
○ Follow symptom
fluctuation longitudinally
16
Proprietary
and
Confidential
Property
of
UCB
16
Proprietary
and
Confidential
Property
of
UCB
Added Bonuses
● More realistic
measures of patients’
lived experiences
● Identify potential
adverse events
earlier
● Can be used for
protocol
design/informing
future studies
17
Proprietary
and
Confidential
Property
of
UCB
17
Proprietary
and
Confidential
Property
of
UCB
TRADITIONAL DIGITAL
SOLUTIONS
No
symptoms
First
symptoms
Diagnosis
Treatment
Therapy
cycles & changes
Outcome
See Doctor
Pharma Core Business
Digital Paradigm Status Quo
• Pt Support Programs
• Connected devices
• Proprietary patient
apps
• Branded websites
Narrow window into
patient journey and
limited scope of support
18
Proprietary
and
Confidential
Property
of
UCB
18
Proprietary
and
Confidential
Property
of
UCB
TRADITIONAL DIGITAL
SOLUTIONS
No
sympto
ms
First
symptoms
Diagnosis
Treatment
Therapy
cycles & changes
Outcome
Booking
Pharma Core Business
Digital Paradigm with a Platform Approach
• PSP
• Connected devices
• Proprietary patient apps
• Branded websites
• Reach a wider population
• Leverage network effects
• Address specific needs at
various time points
PLATFORM-ENABLED OPPORTUNITY
19
Proprietary
and
Confidential
Property
of
UCB
19
Proprietary
and
Confidential
Property
of
UCB
Challenges of dBMs in Clinical Development
● Existing gold standards
(either not good to begin with
or one does not exist)
● Many trials currently using
dBMs as exploratory
endpoints, need to move to
evolving them towards
primary and secondary
endpoints
20
Proprietary
and
Confidential
Property
of
UCB
20
Proprietary
and
Confidential
Property
of
UCB
What Do We Want to Achieve?
● Ability to digitally
phenotype/sub-categorize
participants to enrich trial
population at enrollment and
increase the likelihood of detecting
response to treatment
● Reduce the need for participant
travel
● Shorten clinical trial duration
21
Proprietary
and
Confidential
Property
of
UCB
21
Proprietary
and
Confidential
Property
of
UCB
What Do We Want to Achieve?
● Increased engagement and adoption
● Increased commercial viability of products and
solutions, utilizing new business models to pursue
■ Label expansion
■ Outcomes research used for reimbursement
■ Scale of solutions which reduce healthcare costs
22
Proprietary
and
Confidential
Property
of
UCB
22
Proprietary
and
Confidential
Property
of
UCB
What is the Right Regulatory Pathway for Products Using dBMs?
Is your
dBM is a
part of a
product?
■ De Novo
■ 510k
■ PMA
23
Proprietary
and
Confidential
Property
of
UCB
23
Proprietary
and
Confidential
Property
of
UCB
Why Are dBMs Important in Healthcare?
● Earlier disease detection
● More accurate diagnoses
● Monitoring of disease progression
● Delivery of timely interventions
● Personalized treatment plans
● Inform public health decision-making
● Allows patients to participate in their own
healthcare in a more proactive and informed way
● Improve the quality of information available to HCPs
24
Proprietary
and
Confidential
Property
of
UCB
24
Proprietary
and
Confidential
Property
of
UCB
How Will We Integrate dBMs Into Clinical Practice?
● Ensure validation for clinical use
○ reliable, accurate, sensitive,
and specific for the condition it is
intended to diagnose/monitor
● Integrate dBM into clinical workflow
(into the EHR, etc.)
○ Establish protocols for correct
usage, subsequent course of action
○ Regularly review data & outcomes,
adjust protocols
25
Proprietary
and
Confidential
Property
of
UCB
25
Proprietary
and
Confidential
Property
of
UCB
How Will We Integrate dBMs Into Clinical Practice?
● Staff training and
education
○ Ensure HCPs know
how to interpret
data/insights, properly
follow product’s
indications for use
● Work with policy experts
to inform policy and
guidance
26
Proprietary
and
Confidential
Property
of
UCB
26
Proprietary
and
Confidential
Property
of
UCB
Common Missteps
● Slow decision making and
tendency to over-engineer digital
solutions
● Underestimation of the complexity
and many layers of decision making
required
● Over-reliance on external partners
● To move from buy to build we need
more mature internal tools,
processes, and procedures
27
Proprietary
and
Confidential
Property
of
UCB
27
Proprietary
and
Confidential
Property
of
UCB
Where Do Folks Go Wrong?
Digital health is treated as a separate function of
the business, rather than an intrinsic driver or
enabler of a broader integrated engagement
and experience strategy around patients
28
Proprietary
and
Confidential
Property
of
UCB
28
Proprietary
and
Confidential
Property
of
UCB
Remaining Work, As An Industry
Continuous refinement of standardized definitions,
validation criteria, and data security protocols
Democratization of digital knowhow and
capabilities across organizations at an enterprise
level
Advancement of nascent regulatory pathways and
reimbursement policies
29
Proprietary
and
Confidential
Property
of
UCB
29
Proprietary
and
Confidential
Property
of
UCB
Need for Collaboration Among Key Stakeholders
Tech
Companies
Researchers
Healthcare
Providers
Patients
*pre-competitive,
data-sharing
consortia are key
here
30
Proprietary
and
Confidential
Property
of
UCB
30
Proprietary
and
Confidential
Property
of
UCB
What Does All of This Mean?
A frame shift aligning our corporate
strategic objectives with what patients
and healthcare providers value (and their
pain points)
31
Proprietary
and
Confidential
Property
of
UCB
31
Proprietary
and
Confidential
Property
of
UCB
UCB
@UCBUSA
facebook.com/UCBbiopharma
www.ucb-usa.com
Thank You!
Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB

More Related Content

Similar to Transforming Clinical Development through Digital Biomarkers.pptx.pdf

(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
(CORP02)_inVentiv_Health_Clinical_Overview_Brochure(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
(CORP02)_inVentiv_Health_Clinical_Overview_BrochureJane Hibberd
 
Delivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and valueDelivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and valueKishan Patel, MBA
 
M-health for cost savings and care management
M-health for cost savings and care managementM-health for cost savings and care management
M-health for cost savings and care managementAndy Arends
 
Real World Late Phase The right approach for the right question
Real World Late Phase The right approach for the right questionReal World Late Phase The right approach for the right question
Real World Late Phase The right approach for the right questionSatish Kumar
 
Opportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
Opportunities and Challenges of Mobile Health, Wearables and Sensors for PharmaOpportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
Opportunities and Challenges of Mobile Health, Wearables and Sensors for PharmaJohn Reites
 
InnaMed Introducation
InnaMed IntroducationInnaMed Introducation
InnaMed IntroducationInnaMed Inc.
 
Innovative Policies: Using ACO Principles and Financial Incentives to Improve...
Innovative Policies: Using ACO Principles and Financial Incentives to Improve...Innovative Policies: Using ACO Principles and Financial Incentives to Improve...
Innovative Policies: Using ACO Principles and Financial Incentives to Improve...AHRQ Health Care Innovations Exchange
 
NHS SE presentation
NHS SE presentationNHS SE presentation
NHS SE presentationJisc
 
Disrupting Conventional Therapies with Digital Therapies
Disrupting Conventional Therapies with Digital TherapiesDisrupting Conventional Therapies with Digital Therapies
Disrupting Conventional Therapies with Digital TherapiesMedullan
 
Deborah Weinswig's Digital Health Presentation for NACDS Aug. 24, 2015
Deborah Weinswig's Digital Health Presentation for NACDS Aug. 24, 2015Deborah Weinswig's Digital Health Presentation for NACDS Aug. 24, 2015
Deborah Weinswig's Digital Health Presentation for NACDS Aug. 24, 2015Deborah Weinswig
 
UKADC System Partners Meeting
UKADC System Partners MeetingUKADC System Partners Meeting
UKADC System Partners MeetingScott Buckler
 
So, My FitBit is Clinical Trial Grade Right?
So, My FitBit is Clinical Trial Grade Right?So, My FitBit is Clinical Trial Grade Right?
So, My FitBit is Clinical Trial Grade Right?PAREXEL International
 
SILS 2015 - Innovation at GE Healthcare
SILS 2015 - Innovation at GE HealthcareSILS 2015 - Innovation at GE Healthcare
SILS 2015 - Innovation at GE HealthcareSherbrooke Innopole
 
Healthcare: Innovate or Die | HackLaunch Inaugural Event
Healthcare: Innovate or Die | HackLaunch Inaugural EventHealthcare: Innovate or Die | HackLaunch Inaugural Event
Healthcare: Innovate or Die | HackLaunch Inaugural EventJulien de Salaberry
 
Corporate Brochure (WEB)
Corporate Brochure (WEB)Corporate Brochure (WEB)
Corporate Brochure (WEB)Graham Wood
 
SBM 2013 - Anthony Kouyate (presentation final) - WellDoc
SBM 2013 - Anthony Kouyate (presentation final) - WellDocSBM 2013 - Anthony Kouyate (presentation final) - WellDoc
SBM 2013 - Anthony Kouyate (presentation final) - WellDocRobin Anthony Kouyate, PhD
 
How to intervene early: Examples in depression, epilepsy and smoking cessation
How to intervene early: Examples in depression, epilepsy and smoking cessationHow to intervene early: Examples in depression, epilepsy and smoking cessation
How to intervene early: Examples in depression, epilepsy and smoking cessationSharpBrains
 
Pharma & Health Conference 2017, Francois Clerin
Pharma & Health Conference 2017, Francois ClerinPharma & Health Conference 2017, Francois Clerin
Pharma & Health Conference 2017, Francois ClerinStarttech Ventures
 
Helping you understand the market opportunities of mobile health & medica...
Helping you understand the market opportunities of mobile health & medica...Helping you understand the market opportunities of mobile health & medica...
Helping you understand the market opportunities of mobile health & medica...Damon Lightley
 

Similar to Transforming Clinical Development through Digital Biomarkers.pptx.pdf (20)

(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
(CORP02)_inVentiv_Health_Clinical_Overview_Brochure(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
(CORP02)_inVentiv_Health_Clinical_Overview_Brochure
 
Delivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and valueDelivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and value
 
M-health for cost savings and care management
M-health for cost savings and care managementM-health for cost savings and care management
M-health for cost savings and care management
 
Real World Late Phase The right approach for the right question
Real World Late Phase The right approach for the right questionReal World Late Phase The right approach for the right question
Real World Late Phase The right approach for the right question
 
Opportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
Opportunities and Challenges of Mobile Health, Wearables and Sensors for PharmaOpportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
Opportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
 
2016 iHT2 San Diego Health IT Summit
2016 iHT2 San Diego Health IT Summit2016 iHT2 San Diego Health IT Summit
2016 iHT2 San Diego Health IT Summit
 
InnaMed Introducation
InnaMed IntroducationInnaMed Introducation
InnaMed Introducation
 
Innovative Policies: Using ACO Principles and Financial Incentives to Improve...
Innovative Policies: Using ACO Principles and Financial Incentives to Improve...Innovative Policies: Using ACO Principles and Financial Incentives to Improve...
Innovative Policies: Using ACO Principles and Financial Incentives to Improve...
 
NHS SE presentation
NHS SE presentationNHS SE presentation
NHS SE presentation
 
Disrupting Conventional Therapies with Digital Therapies
Disrupting Conventional Therapies with Digital TherapiesDisrupting Conventional Therapies with Digital Therapies
Disrupting Conventional Therapies with Digital Therapies
 
Deborah Weinswig's Digital Health Presentation for NACDS Aug. 24, 2015
Deborah Weinswig's Digital Health Presentation for NACDS Aug. 24, 2015Deborah Weinswig's Digital Health Presentation for NACDS Aug. 24, 2015
Deborah Weinswig's Digital Health Presentation for NACDS Aug. 24, 2015
 
UKADC System Partners Meeting
UKADC System Partners MeetingUKADC System Partners Meeting
UKADC System Partners Meeting
 
So, My FitBit is Clinical Trial Grade Right?
So, My FitBit is Clinical Trial Grade Right?So, My FitBit is Clinical Trial Grade Right?
So, My FitBit is Clinical Trial Grade Right?
 
SILS 2015 - Innovation at GE Healthcare
SILS 2015 - Innovation at GE HealthcareSILS 2015 - Innovation at GE Healthcare
SILS 2015 - Innovation at GE Healthcare
 
Healthcare: Innovate or Die | HackLaunch Inaugural Event
Healthcare: Innovate or Die | HackLaunch Inaugural EventHealthcare: Innovate or Die | HackLaunch Inaugural Event
Healthcare: Innovate or Die | HackLaunch Inaugural Event
 
Corporate Brochure (WEB)
Corporate Brochure (WEB)Corporate Brochure (WEB)
Corporate Brochure (WEB)
 
SBM 2013 - Anthony Kouyate (presentation final) - WellDoc
SBM 2013 - Anthony Kouyate (presentation final) - WellDocSBM 2013 - Anthony Kouyate (presentation final) - WellDoc
SBM 2013 - Anthony Kouyate (presentation final) - WellDoc
 
How to intervene early: Examples in depression, epilepsy and smoking cessation
How to intervene early: Examples in depression, epilepsy and smoking cessationHow to intervene early: Examples in depression, epilepsy and smoking cessation
How to intervene early: Examples in depression, epilepsy and smoking cessation
 
Pharma & Health Conference 2017, Francois Clerin
Pharma & Health Conference 2017, Francois ClerinPharma & Health Conference 2017, Francois Clerin
Pharma & Health Conference 2017, Francois Clerin
 
Helping you understand the market opportunities of mobile health & medica...
Helping you understand the market opportunities of mobile health & medica...Helping you understand the market opportunities of mobile health & medica...
Helping you understand the market opportunities of mobile health & medica...
 

More from Emily Kunka, MS, CCRP

Case Study_ AI in the Life Sciences Industry.pptx
Case Study_ AI in the Life Sciences Industry.pptxCase Study_ AI in the Life Sciences Industry.pptx
Case Study_ AI in the Life Sciences Industry.pptxEmily Kunka, MS, CCRP
 
Forecasts for the future of DCTs.pptx (2).pdf
Forecasts for the future of DCTs.pptx (2).pdfForecasts for the future of DCTs.pptx (2).pdf
Forecasts for the future of DCTs.pptx (2).pdfEmily Kunka, MS, CCRP
 
Understanding Digital Therapeutics: Journey into Imagination
Understanding Digital Therapeutics: Journey into ImaginationUnderstanding Digital Therapeutics: Journey into Imagination
Understanding Digital Therapeutics: Journey into ImaginationEmily Kunka, MS, CCRP
 
Pediatric lupus case study 11 march2020
Pediatric lupus case study 11 march2020Pediatric lupus case study 11 march2020
Pediatric lupus case study 11 march2020Emily Kunka, MS, CCRP
 
Wearable biosensors in movement disorders
Wearable biosensors in movement disordersWearable biosensors in movement disorders
Wearable biosensors in movement disordersEmily Kunka, MS, CCRP
 
Navigating the Complexity of Virtual Clinical Trials
Navigating the Complexity of Virtual Clinical TrialsNavigating the Complexity of Virtual Clinical Trials
Navigating the Complexity of Virtual Clinical TrialsEmily Kunka, MS, CCRP
 
Digital landscape in neurodegeneration
Digital landscape in neurodegenerationDigital landscape in neurodegeneration
Digital landscape in neurodegenerationEmily Kunka, MS, CCRP
 
Incorporating tech into your business strategy.pptx (1)
Incorporating tech into your business strategy.pptx (1)Incorporating tech into your business strategy.pptx (1)
Incorporating tech into your business strategy.pptx (1)Emily Kunka, MS, CCRP
 

More from Emily Kunka, MS, CCRP (11)

Case Study_ AI in the Life Sciences Industry.pptx
Case Study_ AI in the Life Sciences Industry.pptxCase Study_ AI in the Life Sciences Industry.pptx
Case Study_ AI in the Life Sciences Industry.pptx
 
Forecasts for the future of DCTs.pptx (2).pdf
Forecasts for the future of DCTs.pptx (2).pdfForecasts for the future of DCTs.pptx (2).pdf
Forecasts for the future of DCTs.pptx (2).pdf
 
Understanding Digital Therapeutics: Journey into Imagination
Understanding Digital Therapeutics: Journey into ImaginationUnderstanding Digital Therapeutics: Journey into Imagination
Understanding Digital Therapeutics: Journey into Imagination
 
Pediatric lupus case study 11 march2020
Pediatric lupus case study 11 march2020Pediatric lupus case study 11 march2020
Pediatric lupus case study 11 march2020
 
Wearable biosensors in movement disorders
Wearable biosensors in movement disordersWearable biosensors in movement disorders
Wearable biosensors in movement disorders
 
Navigating the Complexity of Virtual Clinical Trials
Navigating the Complexity of Virtual Clinical TrialsNavigating the Complexity of Virtual Clinical Trials
Navigating the Complexity of Virtual Clinical Trials
 
Digital biomarker development.pptx
Digital biomarker development.pptxDigital biomarker development.pptx
Digital biomarker development.pptx
 
Digital landscape in neurodegeneration
Digital landscape in neurodegenerationDigital landscape in neurodegeneration
Digital landscape in neurodegeneration
 
DTx Development
DTx DevelopmentDTx Development
DTx Development
 
Incorporating tech into your business strategy.pptx (1)
Incorporating tech into your business strategy.pptx (1)Incorporating tech into your business strategy.pptx (1)
Incorporating tech into your business strategy.pptx (1)
 
Oncology experience & case study
Oncology experience & case studyOncology experience & case study
Oncology experience & case study
 

Recently uploaded

Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment BookingModels Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Bookingnarwatsonia7
 
Russian Call Girls South Delhi | 9711199171 | High Profile -New Model -Availa...
Russian Call Girls South Delhi | 9711199171 | High Profile -New Model -Availa...Russian Call Girls South Delhi | 9711199171 | High Profile -New Model -Availa...
Russian Call Girls South Delhi | 9711199171 | High Profile -New Model -Availa...satishsharma69855
 
Globalny raport: „Prawdziwe piękno 2024" od Dove
Globalny raport: „Prawdziwe piękno 2024" od DoveGlobalny raport: „Prawdziwe piękno 2024" od Dove
Globalny raport: „Prawdziwe piękno 2024" od Doveagatadrynko
 
Learn Tips for Managing Chemobrain or Mental Fogginess
Learn Tips for Managing Chemobrain or Mental FogginessLearn Tips for Managing Chemobrain or Mental Fogginess
Learn Tips for Managing Chemobrain or Mental Fogginessbkling
 
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts ServiceCall Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Servicenarwatsonia7
 
Rohini Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
Rohini Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...Rohini Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
Rohini Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...ddev2574
 
Gurgaon Sector 86 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 86 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...Gurgaon Sector 86 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 86 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...ggsonu500
 
The future of change - strategic translation
The future of change - strategic translationThe future of change - strategic translation
The future of change - strategic translationHelenBevan4
 
Gurgaon Sector 45 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 45 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...Gurgaon Sector 45 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 45 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...vrvipin164
 
2024 HCAT Healthcare Technology Insights
2024 HCAT Healthcare Technology Insights2024 HCAT Healthcare Technology Insights
2024 HCAT Healthcare Technology InsightsHealth Catalyst
 
Russian Escorts Pragati Maidan 9711199171 all area service available
Russian Escorts Pragati Maidan 9711199171 all area service availableRussian Escorts Pragati Maidan 9711199171 all area service available
Russian Escorts Pragati Maidan 9711199171 all area service availableveenita788
 
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...Dr. David Greene Arizona
 
Text Neck Syndrome and its probable way out.pptx
Text Neck Syndrome and its probable way out.pptxText Neck Syndrome and its probable way out.pptx
Text Neck Syndrome and its probable way out.pptxProf. Satyen Bhattacharyya
 
MVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady PresentationMVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady PresentationMVP Health Care
 
Call Girls Dwarka 9999965857 Cheap & Best with original Photos
Call Girls Dwarka 9999965857 Cheap & Best with original PhotosCall Girls Dwarka 9999965857 Cheap & Best with original Photos
Call Girls Dwarka 9999965857 Cheap & Best with original Photosparshadkalavatidevi7
 
Call Girls Defence Colony 9999965857 Cheap & Best with original Photos
Call Girls Defence Colony 9999965857 Cheap & Best with original PhotosCall Girls Defence Colony 9999965857 Cheap & Best with original Photos
Call Girls Defence Colony 9999965857 Cheap & Best with original Photosparshadkalavatidevi7
 
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdfeurohealthleaders
 
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
2025 Inpatient Prospective Payment System (IPPS) Proposed RuleShelby Lewis
 
Russian Escorts Greater Kailash | 9711199171 | all area service available
Russian Escorts Greater Kailash | 9711199171 | all area service availableRussian Escorts Greater Kailash | 9711199171 | all area service available
Russian Escorts Greater Kailash | 9711199171 | all area service availableveenita788
 

Recently uploaded (20)

Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment BookingModels Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
Models Call Girls Electronic City | 7001305949 At Low Cost Cash Payment Booking
 
Russian Call Girls South Delhi | 9711199171 | High Profile -New Model -Availa...
Russian Call Girls South Delhi | 9711199171 | High Profile -New Model -Availa...Russian Call Girls South Delhi | 9711199171 | High Profile -New Model -Availa...
Russian Call Girls South Delhi | 9711199171 | High Profile -New Model -Availa...
 
Globalny raport: „Prawdziwe piękno 2024" od Dove
Globalny raport: „Prawdziwe piękno 2024" od DoveGlobalny raport: „Prawdziwe piękno 2024" od Dove
Globalny raport: „Prawdziwe piękno 2024" od Dove
 
Learn Tips for Managing Chemobrain or Mental Fogginess
Learn Tips for Managing Chemobrain or Mental FogginessLearn Tips for Managing Chemobrain or Mental Fogginess
Learn Tips for Managing Chemobrain or Mental Fogginess
 
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts ServiceCall Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
Call Girl Service ITPL - [ Cash on Delivery ] Contact 7001305949 Escorts Service
 
Rohini Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
Rohini Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...Rohini Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
Rohini Sector 6 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few Cl...
 
Gurgaon Sector 86 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 86 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...Gurgaon Sector 86 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 86 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
 
Kidney Transplant At Hiranandani Hospital
Kidney Transplant At Hiranandani HospitalKidney Transplant At Hiranandani Hospital
Kidney Transplant At Hiranandani Hospital
 
The future of change - strategic translation
The future of change - strategic translationThe future of change - strategic translation
The future of change - strategic translation
 
Gurgaon Sector 45 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 45 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...Gurgaon Sector 45 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
Gurgaon Sector 45 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few ...
 
2024 HCAT Healthcare Technology Insights
2024 HCAT Healthcare Technology Insights2024 HCAT Healthcare Technology Insights
2024 HCAT Healthcare Technology Insights
 
Russian Escorts Pragati Maidan 9711199171 all area service available
Russian Escorts Pragati Maidan 9711199171 all area service availableRussian Escorts Pragati Maidan 9711199171 all area service available
Russian Escorts Pragati Maidan 9711199171 all area service available
 
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
Innovations in Nephrology by Dr. David Greene Stem Cell Potential and Progres...
 
Text Neck Syndrome and its probable way out.pptx
Text Neck Syndrome and its probable way out.pptxText Neck Syndrome and its probable way out.pptx
Text Neck Syndrome and its probable way out.pptx
 
MVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady PresentationMVP Health Care City of Schenectady Presentation
MVP Health Care City of Schenectady Presentation
 
Call Girls Dwarka 9999965857 Cheap & Best with original Photos
Call Girls Dwarka 9999965857 Cheap & Best with original PhotosCall Girls Dwarka 9999965857 Cheap & Best with original Photos
Call Girls Dwarka 9999965857 Cheap & Best with original Photos
 
Call Girls Defence Colony 9999965857 Cheap & Best with original Photos
Call Girls Defence Colony 9999965857 Cheap & Best with original PhotosCall Girls Defence Colony 9999965857 Cheap & Best with original Photos
Call Girls Defence Colony 9999965857 Cheap & Best with original Photos
 
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Denmark's Healthcare.pdf
 
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
2025 Inpatient Prospective Payment System (IPPS) Proposed Rule
 
Russian Escorts Greater Kailash | 9711199171 | all area service available
Russian Escorts Greater Kailash | 9711199171 | all area service availableRussian Escorts Greater Kailash | 9711199171 | all area service available
Russian Escorts Greater Kailash | 9711199171 | all area service available
 

Transforming Clinical Development through Digital Biomarkers.pptx.pdf